Holen Sie sich die Stockscreener-App
12.21
3.21%
0.38
Handel nachbörslich:
12.21
Schlusskurs vom Vortag:
$11.83
Offen:
$11.88
24-Stunden-Volumen:
1.18M
Relative Volume:
0.76
Marktkapitalisierung:
$1.34B
Einnahmen:
$-249.00K
Nettoeinkommen (Verlust:
$-187.60M
KGV:
-4.884
EPS:
-2.5
Netto-Cashflow:
$-201.88M
1W Leistung:
+6.92%
1M Leistung:
-7.78%
6M Leistung:
+68.65%
1J Leistung:
+223.87%
1-Tages-Spanne:
$11.77
$12.50
1-Wochen-Bereich:
$10.83
$12.50
52-Wochen-Spanne:
$2.865
$16.96
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Firmenname
Amylyx Pharmaceuticals Inc
Sektor
Telefon
617-683-0917
Adresse
43 THORNDIKE STREET, CAMBRIDGE
Vergleichen Sie AMLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
12.21 | 1.30B | -249.00K | -187.60M | -201.88M | -2.50 |
|
ZTS
Zoetis Inc
|
127.17 | 55.90B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.31 | 51.72B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.91 | 44.71B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.01 | 37.30B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
RGC
Regencell Bioscience Holdings Ltd
|
45.79 | 20.48B | 0 | -5.87M | -767.30K | -0.45 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-06-24 | Eingeleitet | Guggenheim | Buy |
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2025-05-30 | Eingeleitet | TD Cowen | Buy |
| 2025-04-07 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-11-18 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-03-18 | Herabstufung | Mizuho | Buy → Neutral |
| 2024-03-11 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-03-08 | Herabstufung | Goldman | Buy → Neutral |
| 2024-01-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-07-24 | Hochstufung | Goldman | Neutral → Buy |
| 2023-03-31 | Eingeleitet | Mizuho | Buy |
| 2023-01-05 | Eingeleitet | BofA Securities | Buy |
| 2022-05-25 | Eingeleitet | Citigroup | Buy |
| 2022-04-01 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Amylyx Pharmaceuticals Inc Aktie (AMLX) Neueste Nachrichten
Amylyx Pharmaceuticals (AMLX) Announces the Selection of AMX0318 as Development Candidate for PBH and Other Rare Diseases - Yahoo Finance
Buy Rating on Amylyx: Avexitide’s High Unmet Need, Strong PBH Opportunity, and Clear Phase III Catalyst Support Upside - TipRanks
Amylyx selects AMX-0318 as development candidate - BioWorld MedTech
Amylyx selects AMX0318 as development candidate for PBH - Yahoo Finance
Is Amylyx Pharmaceuticals Inc. stock recession proofJuly 2025 Reactions & Stepwise Entry/Exit Trade Alerts - ulpravda.ru
Why Amylyx Pharmaceuticals Inc. stock could outperform in 2025Treasury Yields & Community Consensus Stock Picks - ulpravda.ru
Top Amylyx Executives Quietly Cash Out in Coordinated Stock Moves - TipRanks
Mizuho reiterates Outperform rating on Amylyx stock, cites GLP-1 program - Investing.com
Amylyx Advances AMX0318 as New Rare-Disease Candidate - TipRanks
Amylyx Pharmaceuticals, Inc. Announces Development of AMX0318 - TradingView — Track All Markets
Long-acting GLP-1 antagonist named for rare post-bariatric hypoglycemia - Stock Titan
Will Amylyx Pharmaceuticals Inc. stock deliver long term returns2026 world cup usa national team semifinals top scorers set piece tactics tactical prediction breakdown - ulpravda.ru
Amylyx Pharmaceuticals Q3 2025 Earnings Preview - MSN
Amylyx Pharmaceuticals pushes for novel therapy development - Traders Union
Relative Strength Alert For Amylyx Pharmaceuticals - Nasdaq
Assessing Amylyx Pharmaceuticals (AMLX) Valuation After Insider Buying And AMX0114 Trial Progress - Sahm
Amylyx Pharmaceuticals Stock (AMLX) Opinions on Insider Purchase and Clinical Data - Quiver Quantitative
Amylyx Pharmaceuticals (AMLX) Price Target Increased by 12.96% to 20.74 - MSN
Amylyx Pharmaceuticals (NASDAQ:AMLX) Trading Down 7.2%Time to Sell? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect - ACCESS Newswire
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Guidance Update: What margin trends mean for Amylyx Pharmaceuticals Inc stockPortfolio Return Summary & Daily Oversold Bounce Ideas - moha.gov.vn
Hedge Fund and Insider Trading News: Ken Griffin, Ray Dalio, Warren Buffett, Toms Capital, Ken Fisher, Pershing Square, Amylyx Pharmaceuticals Inc (AMLX), NVIDIA Corp (NVDA), and More - Insider Monkey
Amylyx Pharmaceuticals Stock (AMLX) Opinions on Insider Purchase - Quiver Quantitative
Amylyx announces proposed public offering of common stock - MSN
How Investors Are Reacting To Amylyx Pharmaceuticals (AMLX) Early AMX0114 Safety Data And Insider Buying - Sahm
Amylyx Pharma director Firestone buys $100k in AMLX stock By Investing.com - Investing.com UK
Amylyx Pharma director Firestone buys $100k in AMLX stock - Investing.com
Amylyx Pharmaceuticals (NASDAQ:AMLX) Director Acquires $100,845.00 in Stock - MarketBeat
Amylyx Pharmaceuticals Director Karen Firestone Acquires 8,100 Shares - TradingView — Track All Markets
How Amylyx Pharmaceuticals Inc. stock trades before earningsLayoff News & Verified Momentum Watchlists - Улправда
Will Amylyx Pharmaceuticals Inc. stock recover faster than peers2025 Key Lessons & Real-Time Chart Pattern Alerts - Улправда
Bank of America Securities Keeps Their Buy Rating on Amylyx Pharmaceuticals Inc (AMLX) - The Globe and Mail
Amylyx Pharmaceuticals (NASDAQ:AMLX) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Will Amylyx Pharmaceuticals Inc. stock return to pre crisis levelsBull Run & Expert Approved Momentum Trade Ideas - Улправда
Will Amylyx Pharmaceuticals Inc. stock benefit from sector rotation2025 Institutional Moves & Stock Timing and Entry Methods - Улправда
What margin trends mean for Amylyx Pharmaceuticals Inc. stockMarket Activity Summary & High Conviction Buy Zone Picks - DonanımHaber
Is Amylyx Pharmaceuticals Inc. stock trading at a premium valuationEarnings Summary Report & Weekly Sector Rotation Insights - ulpravda.ru
AMLX FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 9 Deadline in Securities Class ActionAMLX - TMX Newsfile
Amylyx Pharmaceuticals Earnings Notes - Trefis
TFG Asset Management GP Ltd Makes New $1.40 Million Investment in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
683 Capital Management LLC Has $13.85 Million Stake in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
ALS medication AMX0114 shows safety, moves to 2nd trial group - ALS News Today
Amylyx pins its next hopes on a niche drug in the obesity space - Pharma Voice
Is Early AMX0114 Safety Data Altering The Investment Case For Amylyx Pharmaceuticals (AMLX)? - Yahoo Finance
Is Amylyx Pharmaceuticals (AMLX) Overvalued After Its 250% Year‑to‑Date Share Price Surge? - Sahm
Amylyx presents safety outcomes of AMX0114 in LUMINA study - MSN
Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow? - Nasdaq
Amylyx Pharmaceuticals Inc (AMLX) Receives a Buy from Mizuho Securities - The Globe and Mail
Rare Disease Leaders Call for Regulatory Consistency After Chaotic Year - BioSpace
Amylyx’s ALS drug AMX0114 shows positive early safety data By Investing.com - Investing.com Nigeria
Finanzdaten der Amylyx Pharmaceuticals Inc-Aktie (AMLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Amylyx Pharmaceuticals Inc-Aktie (AMLX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Cohen Joshua B | Co-Chief Executive Officer |
Jan 06 '26 |
Sale |
11.09 |
7,715 |
85,596 |
3,317,632 |
| Klee Justin B. | Co-Chief Executive Officer |
Jan 06 '26 |
Sale |
11.09 |
7,715 |
85,589 |
3,317,586 |
0.37%
1.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):